Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2007 Nov;7(11):1739-47.

Anti-IgE in allergic asthma and rhinitis: an update.

Author information

1
Southampton General Hospital, Infection, Inflammation & Repair, Mailpoint 810, Level F, South Block, SO16 7LS, Southampton, UK.

Abstract

Allergic asthma and rhinitis imposes a huge burden in terms of treatment costs, productivity loss and hospital admissions. IgE plays a significant role in the manifestation of these conditions and the identification of a monoclonal antibody that binds to IgE provides clinicians another therapeutic strategy in the management of these conditions. Blocking the effects of IgE by omalizumab, a recombinant humanized monoclonal antibody that selectively binds to IgE has been shown to be a useful adjunct in the treatment of allergic asthma and rhinitis. Omalizumab is effective as a steroid reducing agent in patients with severe asthma and is successful in decreasing asthma exacerbations. Omalizumab was well tolerated in clinical trials, however, the potential long-term side effects need careful monitoring. The high cost of the molecule could make this a therapeutic option in a small proportion of patients in whom there is a large unmet need.

PMID:
17961096
DOI:
10.1517/14712598.7.11.1739
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center